SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2008 / Cilt: 32 - Sayı: 5

Novel Analogues of 2-Pyrazoline: Synthesis, Characterization, and Antimycobacterial Evaluation

Ahmet ÖZDEMİR
Gülhan TURAN-ZITOUNI
Zafer Asım KAPLANCIKLI
Pages
529–538
Publication Date
2008-05-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The preliminary results showed that all of the tested compounds were inactive against the test organism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fourteen new 1-[(N,N-disubstitutedthiocarbamoylthio)acetyl]- 3-(2-thienyl)-5-aryl-2-pyrazoline derivatives were synthesized by reacting 1-(chloroacetyl)-3-(2-thienyl)-5-aryl-2-pyrazolines and appropriate sodium salts of N,N-disubstituted dithiocarbamoic acids in acetone.
📊
Key Findings & Data:The structures of the synthesized compounds were confirmed by UV, IR, 1H-NMR, and FAB+-MS spectral data.
💡
Conclusion & Impact:The preliminary results showed that all of the tested compounds were inactive against the test organism.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:2-Pyrazolines · Sodium salts of N · N-disubstituted dithiocarbamoic acids

Abstract

Fourteen new 1-[(N,N-disubstitutedthiocarbamoylthio)acetyl]- 3-(2-thienyl)-5-aryl-2-pyrazoline derivatives were synthesized by reacting 1-(chloroacetyl)-3-(2-thienyl)-5-aryl-2-pyrazolines and appropriate sodium salts of N,N-disubstituted dithiocarbamoic acids in acetone. The structures of the synthesized compounds were confirmed by UV, IR, 1H-NMR, and FAB+-MS spectral data. The compounds were evaluated for in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv using the BACTEC 460 radiometric system and BACTEC 12B medium. The preliminary results showed that all of the tested compounds were inactive against the test organism.

Özet

Fourteen new 1-[(N,N-disubstitutedthiocarbamoylthio)acetyl]- 3-(2-thienyl)-5-aryl-2-pyrazoline derivatives were synthesized by reacting 1-(chloroacetyl)-3-(2-thienyl)-5-aryl-2-pyrazolines and appropriate sodium salts of N,N-disubstituted dithiocarbamoic acids in acetone. The structures of the synthesized compounds were confirmed by UV, IR, 1H-NMR, and FAB+-MS spectral data. The compounds were evaluated for in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv using the BACTEC 460 radiometric system and BACTEC 12B medium. The preliminary results showed that all of the tested compounds were inactive against the test organism.

🔖

Cite This Article

ÖZDEMİR, A., TURAN-ZITOUNI, G., KAPLANCIKLI, Z. A. (2008). Novel Analogues of 2-Pyrazoline: Synthesis, Characterization, and Antimycobacterial Evaluation. Turkish Journal of Chemistry, Cilt: 32 - Sayı: 5, 529–538. https://ajindex.com/articles/185003

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Levai, A. Chem. Heterocyclic Compd. 1997, 33, 647-659.
  2. Turan-Zitouni, G.; ¨Ozdemir, A.; G¨uven, K. Arch. Pharm. 2005, 338, 96-104.
  3. Turan-Zitouni, G.; ¨Ozdemir, A.; Kaplancıklı, Z.A.; Chevallet, P.; Tunalı, Y. Phosphorus Sulfur 2005, 180, 2724. Kaplancıklı, Z.A.; Turan-Zitouni, G.; ¨Ozdemir, A.; Revial, G.; G¨uven, K. Phosphorus Sulfur 2007, 182, 749-764
  4. Ozdemir, A.; Turan-Zitouni, G.; Kaplancıklı, Z.A.; Revial, G. and G¨uven, K. Eur. J. Med. Chem. 2007, 42, ¨ 409. Shaharyar, M.; Siddiqui, A.A.; Ali, M.A.; Sriram, D.and Yogeeswari, P.; Bioorg. Med. Chem. Lett. 2006, 16, 3949. Nugent, R.A.; Murphy, M.; Schlachter, S.T.; Dunn, C.J.; Smith, R.J.; Staite, N.D.; Galinet, L.A.; Shields, S.K.; Aspar, D.G.; Richard, K.A., and Rohloff, N.A. J. Med. Chem. 1993, 36, 134-139.
  5. Manna, F.; Chimenti, F.; Bolasco, A.; Cenicola, M.L.; D’Amico, M.; Parrillo, C.; Rossi, F. and Marmo, E. Eur. J. Med. Chem. 1992, 27, 633-639.
  6. Bilgin, A.A.; Palaska, E.; Sunal, R. Arzneim. Forsch. Drug Res. 1993, 43, 1041-1044.
  7. Bilgin, A.A.; Palaska, E.; Sunal, R.; G¨um¨usel, B. Pharmazie 1994, 49, 67- 69. Raiford, L.C.; Peterson, W.J. J. Org. Chem. 1937, 1, 544-551.
  8. Raiford, L.C.; Gundy, G.V. J. Org. Chem. 1938, 3, 265-272.
  9. Raiford, L.C.; Manley, R.H. J. Org. Chem. 1940, 5, 590-597.
  10. Wiley, R.H.; Jarboe, C.H.; Hayes, F.N.; Hansbury, E.; Nielsen, J.T.; Callahan, P.X.; Sellars, M.C. J. Org. Chem. 1958, 23, 732-738.
  11. Kabli, R.A.; Khalaf, A.A.; Zimaity, M.T.; Khalil, A.M.; Kaddah, A.M.; Al-Rifaie, H.A. J. Indian Chem. Soc.,68, 47-51.
  12. Mishriky, N.; Asaad, F.M.; Ibrahim, Y.A.; Girgis, A.S. Pharmazie 1996, 51, 544-548.
  13. Manna, F.; Chimenti, F.; Bolasco, A.; Secci, D.; Bizzarri, B.; Befani, O.; Turini, P.; Mondovi, B.; Alcaro, S.; TaŞ, A. Bioorg. Med. Chem. Lett. 2002, 12, 3629-3633.
  14. Levai, A.; Patonay, T.; Silva, A.M.S.; Pinto, D.C.G.A.; Cavaleiro, J.A.S. J. Heterocyclic Chem. 2002, 39, 758. Levai, A. Heterocycl. Commun. 2003, 9, 287-292.
  15. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Befani, O.; Turini, P.; Giovannini, V.; Mondovi, B.; Cirilli, R.; Torre, F. J. Med. Chem. 2004, 47, 2071-2074.
  16. Chimenti, F.; Bizzarri, B.; Manna, F.; Boalsco, A.; Secci, D.; Chimenti, P.; Granese, A.; Rivanera, D.; Lilli, D.; Scaltrito, M.M.; Brenciaglia, M.I. Bioorg. Med. Chem. Lett. 2005, 15, 603-607.
  17. Levai, A.; Jeko, J.; Brahmbhatt, D.I. J. Heterocyclic Chem. 2005, 42, 1231-1235.
  18. Levai, A. J. Heterocyclic Chem. 2005, 39, 1-13.
  19. Levai, A.; Jeko, J. J. Heterocyclic Chem. 2006, 43, 111-115. Khalaf,